Intellia Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $67.7 | $57.9 | $36.3 | $52.1 | $33.1 |
| Operating income | -$441.0 | -$534.3 | -$515.3 | -$458.2 | -$267.9 |
| Net income | -$412.7 | -$519.0 | -$481.2 | -$474.2 | -$267.9 |
| Cash Flow Statement | |||||
| Free cash flow | -$395.9 | -$354.7 | -$408.1 | -$346.8 | -$237.8 |
Shares outstanding 140.1M · Free float 93.9%
Annual filing data through FY ended December 31, 2025; float as of October 3, 2026.